Here are relevant reports on : photodynamic-therapy-market
-
Europe Radiation Detection, Monitoring, and Safety Market By Product (Personal & Area Dosimeters, Material & Full-body Monitors), Component (Gas-filled and Solid-state Detectors), Application (Safety & Security, Diagnostics & Therapy) Forecast to 2031
The Europe radiation detection, monitoring, and safety market is projected to grow from USD 0.83 billion in 2026 to USD 1.37 billion by 2031 at a CAGR of 9.0% during the forecast period. The top players in the Europe radiation detection, monitoring, and safety market are Thermo Fisher Scientific (US), Mirion Technologies, Inc. (US), Fortive (US), Fuji Electric (Japan), Ludlum Measurements, Inc. (US), and Arktis Radiation Detectors Ltd (Switzerland).
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) & Region - Global Forecast to 2028
The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in a forecasted valuation of US$49.0 billion by the end of the period. The growth of this market is characterized by the increasing collaborations and partnerships by major market players, and the emerging applications in new therapeutic areas. Rising focus on personalized medicine and increasing regulatory approvals in regenerative medicine are also predicted to drive the market.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region - Global Forecast to 2028
The global recombinant proteins market, valued at US$2.1 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 7.2% from 2023 to 2028, culminating in a forecasted valuation of US$3.2 billion by the end of the period. Growth in the market can be attributed to factors such as rising incidence of chronic diseases, growing demand for biologics and biosimilars due to expiration of patents, rising demand for customized medicine and increasing government initiatives for R&D in life sciences research.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Cardiac Rhythm Management Market by Product (Implantable, External Pacemakers, Defibrillators, Cardiac resynchronization therapy (CRT) devices), by End-Users (Hospitals, Home, Ambulatory) Forecasts To 2020
The incidence of cardiovascular diseases (CVD) is increasing with the aging population, changing lifestyle, and increasing stress. It is estimated that 17 million people die of CVD every year. Sudden cardiac arrest (SCA) is the leading cause of death among U.S. adults aged 40 years and above. According to Centre for Disease Control and Prevention (CDC), approximately 250,000 people die every year in the U.S. from SCA.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Patient Engagement Solutions Market by Therapy (CVD, Diabetes, Obesity, Fitness), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, Payer, Patient), Unmet Need, Investment, Market Share, Trends - Global Forecast to 2030
The global patient engagement solutions market, valued at US$25.79 billion in 2024, stood at US$29.33 billion in 2025 and is projected to advance at a resilient CAGR of 12.0% from 2025 to 2030, culminating in a forecasted valuation of US$51.69 billion by the end of the period. The patient engagement solutions market is driven by the growing shift toward patient-centric care, rising adoption of digital health technologies, increasing prevalence of chronic diseases, and the expanding use of mobile apps, portals, and remote monitoring tools to support continuous patient interaction
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029
The global gene transfer technologies market, valued at US$3.63 billion in 2023, stood at US$3.73 billion in 2024 and is projected to advance at a resilient CAGR of 9.7% from 2024 to 2029, culminating in a forecasted valuation of US$5.93 billion by the end of the period. The increasing usage in vaccine development and applications in cancer immunotherapy; is one of the major factors driving the growth of the gene transfer technologies market.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028
The global continuous bioprocessing market, valued at US$201 million in 2022, stood at US$218 million in 2023 and is projected to advance at a resilient CAGR of 22.4% from 2023 to 2028, culminating in a forecasted valuation of US$599 million by the end of the period. The growth of the market is largely driven by rising demand for biopharmaceuticals, advantages of continuous bioprocessing over batch/fed-batch mode, and emergence of integrated end-to-end continuous bioprocessing.
- Published: November 2023
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Asia Pacific Patient Engagement Solutions Market by Therapy (Chronic [Obesity, Diabetes], Women’s Health), Functionality (Telehealth, E-Prescribing, Scheduling, Billing), End User (Hospital, ASC, Payer, Patient), Unmet Need, Investment - Forecast to 2030
The Asia Pacific patient engagement solutions market is projected to reach USD 7.48 billion by 2030 from USD 3.97 billion in 2025, at a CAGR of 13.5% during the forecast period. Prominent players in the market include McKesson Corporation (US), Veradigm LLC (US), Oracle (US), athenahealth (US), Health Catalyst (US), Cognizant (US), Oneview Healthcare (Ireland), Epic Systems Corporation (US), Medical Information Technology, Inc. (US), Koninklijke Philips NV (Netherlands), Orion Health (New Zealand), Televox (US), Nuance Communications, Inc. (US) (Microsoft), Experian Information Solutions, Inc. (US), TATA Consultancy Services Limited (India), Optum (US), OPEN Health (UK), DKSH (Switzerland), ZS (US), eClinicalWorks (US), blueBRIX (US), Fortunesoft (India), SONIFI Health Incorporated (US), Genzeon (US), and Advantech Co., Ltd. (Taiwan).
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Monoclonal Antibody Therapeutics Market / mABs Therapeutics Market Size by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
The global monoclonal antibody therapeutics market, valued at US$222.6 billion in 2023, stood at US$252.6 billion in 2024 and is projected to advance at a resilient CAGR of 14.5% from 2024 to 2029, culminating in a forecasted valuation of US$497.5 billion by the end of the period. Driving factors of the market, including clinical trials, encompass increasing prevalence of complex diseases, advancements in biotechnology facilitating targeted treatments, regulatory support expediting approval processes, and robust investments in research and development.
- Published: March 2024
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
